GlassScriptPhysician profile
Craig Caldwell
NPI 1801981592
$2,297.51
in general payments reported to CMS, 2019-2025
28 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $290 · 2021: $244 · 2022: $279 · 2023: $457 · 2024: $381 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $301.85 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $276.20 | 2019-2025 | Veozah |
| Pfizer INC. | $236.88 | 2019-2023 | |
| Lilly USA, LLC | $229.16 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $181.25 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $178.60 | 2019-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $132.65 | 2021-2023 | |
| Gilead Sciences, INC. | $120.80 | 2019 | |
| Merck Sharp & Dohme LLC | $90.82 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $80.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $68.45 | 2021-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.48 | 2022-2024 | Ofev, Synjardy, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $48.14 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.54 | 2020-2022 | |
| Mylan Specialty L.P. | $28.30 | 2024 | Yupelri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $23.32 | 2025 | Fluad, Flucelvax |
| Abbvie INC. | $21.45 | 2023 | Vraylar |
| Corcept Therapeutics | $19.85 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $18.24 | 2024 | Gemtesa |
| Allergan, INC. | $18.05 | 2020 | |
| Vanda Pharmaceuticals INC. | $17.55 | 2021 | |
| Biogen, INC. | $17.43 | 2020 | |
| Bausch Health US, LLC | $16.73 | 2019 | |
| Amarin Pharma, INC. | $15.30 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.91 | 2019 | |
| Esperion Therapeutics, INC. | $14.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.72 | 2019 | |
| Medtronic USA, INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Caldwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.